Table 2.
Susceptibility profiles of 120 Escherichia coli clinical isolates in relation to fluoroquinolone and extended-spectrum-cephalosporin resistance groupa
| Antimicrobial agent or class | No. (%) of isolates susceptible to agent or class within resistance group (n = 40)b |
||
|---|---|---|---|
| FQ-S, ESC-S | FQ-R, ESC-S | FQ-R, ESC-R | |
| Ampicillin | 20 (50) | 5 (12) | 0 (0) |
| Ampicillin-sulbactam | 26 (65) | 13 (23) | 0 (0) |
| Cefazolin | 34 (85) | 29 (12) | 0 (0) |
| Gentamicin | 34 (85) | 27 (67) | 20 (50) |
| Nitrofurantoin | 38 (95) | 37 (92) | 28 (70)c |
| Trimethoprim-sulfamethoxazole | 28 (70) | 22 (55) | 8 (20) |
a
All isolates were susceptible to carbapenems (based on reported ertapenem, imipenem, or meropenem result).
b
FQ-S and FQ-R, fluoroquinolone susceptible and resistant; ESC-S and ESC-R, extended-spectrum-cephalosporin susceptible and resistant.
c
For nitrofurantoin susceptibility among FQ-R, ESC-R ST131 isolates (20/20, 100%) versus non-ST131 isolates (8/20, 40%), P < 0.001 (Fisher's exact test). All other comparisons (ST131 versus non-ST131) yielded P values of >0.10.